OPRM1 Genetic Testing

OPRM1, also know as, MU 1 opioid receptor is a pharmacodynamic receptor that is partially responsible for the effectiveness of some opioids. This receptor is studied in conjunction with substance abuse & dependence as well as pain sensitivity. Like many genes, there has been numerous studies on how genetic variations could potentially effect drug interactions. Specifically, research has been done in connection between naltrexone (Vivitrol®) and this gene. Vivitrol is commonly used to treat alcoholism and addiction to opioids. However genetic variations could affect the efficacy of this medication.

Pharmacogenetic Testing for Vivitrol

Studies on how clinical outcomes can be improved when patients begin vivitrol treatment have included pharmacogenetic data. This data is important in interpreting how individuals with genetic variations may be more or less receptive to medications. Because OPRM1 affects how opioids are received, it is valuable for patients and physicians to understand any underlying genetic reasons medications may have lowered effectiveness.

Addiction Treatments & Genetic Testing

It is recommended that patients who are beginning naltrexone treatment for alcohol dependence get tested for OPRM1 genetic mutations. OPRM1 testing is also valuable in predicting opioid response and dosage requirements for a patient. This can help prevent opioid addiction risks in patients. Patients who have a family history of opioid addiction or other issues with opioids are good candidates for genetic testing.

Order Pharmacogenetic Testing for OPRM1

At TruGenX we provide pharmacogenetic testing for medical providers nationwide. Providers can contact our team to order tests and learn more about the testing process and all of the genes we can test on our panel. Patients who are interested in PGx testing can visit our resources on pharmacogentics. Patients should talk to their doctors about PGx testing and whether or not it is right for them.